keyword
MENU ▼
Read by QxMD icon Read
search

fever neutropenia

keyword
https://www.readbyqxmd.com/read/29893055/phase-i-safety-and-pharmacokinetic-study-of-cipatinib-an-original-dual-tyrosine-kinase-inhibitor
#1
Jiayu Wang, Yiqun Han, Xiuqing Shi, Qing Li, Pin Zhang, Peng Yuan, Fei Ma, Yang Luo, Ruigang Cai, Ying Fan, Shanshan Chen, Qiao Li, Binghe Xu
BACKGROUND: Cipatinib is a novel tyrosine kinase inhibitor against both EGFR and HER2/neu. This phase I trial was conducted to assess the safety, dose-limiting toxicities (DLTs), and maximum-tolerated dose of cipatinib in HER2-positive patients with advanced breast cancer. METHODS: Eligible adults with advanced breast cancer were administered cipatinib 200 mg/day (n = 3) as an initial dose, with escalating dosages of 400 mg (n = 4), 800 mg (n = 2), 1200 mg (n = 3), 1400 mg (n = 3), 1600 mg (n = 3), and 1800 mg (n = 2) in 21 day cycles...
June 12, 2018: Thoracic Cancer
https://www.readbyqxmd.com/read/29889673/a-case-of-severe-pembrolizumab-induced-neutropenia
#2
Barbacki Ariane, Peter G Maliha, Marie Hudson, David Small
Immune checkpoint inhibitors have revolutionized cancer therapy. Given their mechanism of action, immune-related adverse events have been associated with their use. We present the first documented case of pembrolizumab-induced grade IV neutropenia. A 73-year-old women known for myositis, Crohn's disease, and hypothyroidism and diagnosed with PD-L1 positive stage IV pulmonary adenocarcinoma is treated with Pembrolizumab. She develops grade IV neutropenia 2 weeks after her second infusion. She is therefore hospitalized and treated initially with corticosteroids, granulocyte colony-stimulating factor, and intravenous immunoglobulins...
June 8, 2018: Anti-cancer Drugs
https://www.readbyqxmd.com/read/29885367/ecthyma-gangrenosum-vulvar-ulcers-pseudomonas-and-pancytopenia-a-case-report-of-an-18-month-old-female
#3
Nicole Todd, Julia E Boucher, Mylène Bassal, Tania Dumont, Nathalie Fleming
BACKGROUND: An 18-month-old female presenting with severe vulvar ulcers and pancytopenia with investigations revealing P.aeruginosa bacteremia. CASE: Previously healthy 18-month-old female presented with 6 days of fevers, vulvar rash and ulcers. Vulvar cultures demonstrated S.aureus and P.aeruginosa. Bloodwork showed pancytopenia and P.aeruginosa bacteremia. She started broad spectrum antibiotics. Bone marrow aspirate revealed a hypocellular marrow with erythroid dysplasia...
June 6, 2018: Journal of Pediatric and Adolescent Gynecology
https://www.readbyqxmd.com/read/29880613/real-world-outcomes-and-management-strategies-for-venetoclax-treated-chronic-lymphocytic-leukemia-patients-in-the-united-states
#4
Anthony R Mato, Meghan Thompson, John N Allan, Danielle M Brander, John M Pagel, Chaitra S Ujjani, Brian T Hill, Nicole Lamanna, Frederick Lansigan, Ryan Jacobs, Mazyar Shadman, Alan P Skarbnik, Jeffrey J Pu, Paul M Barr, Alison R Sehgal, Bruce D Cheson, Clive S Zent, Hande H Tuncer, Stephen J Schuster, Peter V Pickens, Nirav N Shah, Andre Goy, Allison M Winter, Christine Garcia, Kaitlin Kennard, Krista Isaac, Colleen Dorsey, Lisa M Gashonia, Arun K Singavi, Lindsey E Roeker, Andrew Zelenetz, Annalynn Williams, Christina Howlett, Hanna Weissbrot, Naveed Ali, Sirin Khajavian, Andrea Sitlinger, Eve Tranchito, Joanna Rhodes, Joshua Felsenfeld, Neil Bailey, Bhavisha Patel, Timothy F Burns, Melissa Yacur, Mansi Malhotra, Jakub Svoboda, Richard R Furman, Chadi Nabhan
Venetoclax is a BCL2 inhibitor approved for 17p-deleted relapsed/refractory chronic lymphocytic leukemia with activity following kinase inhibitors. We conducted a multicenter retrospective cohort analysis of patients with CLL treated with venetoclax to describe outcomes, toxicities, and treatment selection following venetoclax discontinuation. A total of 141 chronic lymphocytic leukemia patients were included (98% relapsed/refractory). Median age at venetoclax initiation was 67 years (range 37-91), median prior therapies was 3 (0-11), 81% unmutated IGHV, 45% del(17p), and 26...
June 7, 2018: Haematologica
https://www.readbyqxmd.com/read/29877282/invasive-pulmonary-aspergillosis-in-the-epidural-space-in-a-patient-with-acute-myelogenous-leukemia-with-myelodysplasia-related-changes-a-case-study-and-literature-review-of-vertebral-aspergillosis-in-japan
#5
Ryohei Ono, Shuku Sato, Satomi Okada, Emiko Kanbe, Eri Tanaka, Yotaro Tamai
Vertebral aspergillosis is a rare infectious disease with a high mortality rate. We herein report a 70-year-old woman with acute myelogenous leukemia with myelodysplasia-related changes, nontuberculous mycobacteriosis, and bronchiectasis who presented with a fever and cough. Her clinical symptoms and laboratory test results suggested febrile neutropenia and pneumonia. However, her clinical course was further complicated by lower extremity weakness. Magnetic resonance imaging of the spine showed consolidation contiguously spreading toward the epidural space between the T4 and T5...
June 6, 2018: Internal Medicine
https://www.readbyqxmd.com/read/29871527/through-their-eyes-parental-perceptions-on-hospital-admissions-for-febrile-neutropenia-in-children-with-cancer
#6
Katrina J Anderson, Natalie K Bradford, Julia E Clark
Febrile neutropenia requires prompt assessment and antibiotic administration and is the most common reason for unexpected hospital admission in pediatric oncology. Parents are expected to be vigilant and "drop everything" to take their child to their nearest hospital for assessment if fever occurs. Delays in antibiotic administration are associated with poorer outcomes; however, delays are common. Our aim was to understand and describe the lived experience of parents of children with cancer who received treatment for fever with confirmed/suspected neutropenia...
June 1, 2018: Journal of Pediatric Oncology Nursing: Official Journal of the Association of Pediatric Oncology Nurses
https://www.readbyqxmd.com/read/29869680/reduced-dose-pegfilgrastim-is-associated-with-less-bone-pain-without-increased-neutropenia-a-retrospective-study
#7
Elyse E Lower, Mahmoud Charif, Meg Bartelt
BACKGROUND: Chemotherapy for breast cancer is associated with a high risk of neutropenia. Pegfilgrastim reduces the risk of neutropenic fever but commonly causes bone pain. OBJECTIVE: Evaluate whether a reduced dose of pegfilgrastim (3 mg) reduced the frequency of bone pain without compromising efficacy. METHODS: Records reviewed from breast cancer patients who received at least one 3 mg dose of pegfilgrastim, white blood count (WBC), and absolute granulocyte counts (AGC) were collected...
June 5, 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29866872/primary-fungal-prophylaxis-in-hematological-malignancy-a-network-meta-analysis-of-randomized-controlled-trials
#8
Cho-Hao Lee, Chin Lin, Ching-Liang Ho, Jung-Chung Lin
Several new anti-fungal agents have become available for primary fungal prophylaxis of neutropenia fever in haematological malignancy patients. Our aim was to synthesize all evidence on efficacy and enable an integrated comparison of all current treatments.We performed a systematic literature review to identify all publicly available evidence from randomized controlled trials (RCT). We searched Embase, PubMed, the Cochrane Central Register of Controlled Clinical Trials, and the website www.ClinicalTrials.gov In total, 54 RCTs were identified, including 13 treatment options...
June 4, 2018: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/29850259/safety-assessment-of-neoadjuvant-pertuzumab-combined-with-trastuzumab-in-nonmetastatic-her2-positive-breast-cancer-in-postmenopausal-elderly-women-of-south-asia
#9
Nadia Hussain, Amira S A Said, Zainab Khan
Aim: To evaluate the safety issues and adverse effects of using TCHP regimen (docetaxel, carboplatin, trastuzumab, and pertuzumab) versus TCP regimen (docetaxel, carboplatin, and trastuzumab) in older postmenopausal women with nonmetastatic HER2-positive breast cancer. HER2 overexpressed in 20-25% of breast cancer signals an aggressive form of breast cancer and is treated with trastuzumab and pertuzumab. Methods: The patient record database was accessed to identify all postmenopausal women in the Punjab Care hospital who were above 65 years old, with stages 1-3 HER2-positive breast cancer and treated with neoadjuvant TCHP and neoadjuvant TCP from 2013 till 2016...
2018: International Journal of Breast Cancer
https://www.readbyqxmd.com/read/29849825/novel-biomarker-candidates-for-febrile-neutropenia-in-hematological-patients-using-nontargeted-metabolomics
#10
Marika Lappalainen, Jenna Jokkala, Auni Juutilainen, Sari Hämäläinen, Irma Koivula, Esa Jantunen, Kati Hanhineva, Kari Pulkki
Background: Novel potential small molecular biomarkers for sepsis were analyzed with nontargeted metabolite profiling to find biomarkers for febrile neutropenia after intensive chemotherapy for hematological malignancies. Methods: Altogether, 85 patients were included into this prospective study at the start of febrile neutropenia after intensive chemotherapy for acute myeloid leukemia or after autologous stem cell transplantation. The plasma samples for the nontargeted metabolite profiling analysis by liquid chromatography-mass spectrometry were taken when fever rose over 38° and on the next morning...
2018: Disease Markers
https://www.readbyqxmd.com/read/29846245/dabrafenib-and-trametinib-treatment-associated-fevers-in-metastatic-melanoma-causing-extreme-elevation-in-procalcitonin-in-the-absence-of-infection
#11
Timothy D Clay, Samantha E Bowyer
Febrile illnesses are common in the management of metastatic solid organ malignancies. Traditionally they occur in the setting of immunosuppression and neutropenia owing to cytotoxic therapy necessitating consideration of systemic infections. Systemic markers of inflammation, such as C-reactive protein and procalcitonin (PCT), may be used to assist in determining the aetiology of a fever in such patients. Newer anticancer therapies may cause significant noninfectious fevers and may result in a rise in inflammatory markers, despite the absence of an infection...
May 25, 2018: Anti-cancer Drugs
https://www.readbyqxmd.com/read/29790825/epidemiological-and-clinical-features-of-visceral-leishmaniasis-in-children-in-alicante-province-spain
#12
Jose M Ramos, Agustin Clavijo, Luis Moral, Cesar Gavilan, Tatiana Salvador, Javier González de Dios
Background Visceral leishmaniasis (VL) is endemic to the Mediterranean basin. In children, VL often presents with non-specific symptoms and can be life-threatening without proper treatment. Aim To describe the epidemiological and clinical features of pediatric VL in children in Alicante, Spain. Methods The study included all paediatric (<15 years) cases admitted to three hospitals in the province of Alicante from May 1992 to May 2015 with diagnosis of VL (detection was either by anti-Leishmania antibodies in serology or Leishmania in blood and/or bone marrow aspirates)...
May 23, 2018: Paediatrics and International Child Health
https://www.readbyqxmd.com/read/29783918/rituximab-mediated-late-onset-neutropenia-in-systemic-lupus-erythematosus-distinct-roles-of-baff-and-april
#13
I Parodis, F Söder, F Faustini, Z Kasza, I Samuelsson, A Zickert, E Svenungsson, R F van Vollenhoven, V Malmström, F Wermeling, I Gunnarsson
Objective Rituximab-mediated late-onset neutropenia (LON) has been described in various diseases. We investigated its occurrence, consequences and contributing factors in patients with systemic lupus erythematosus (SLE). Methods Rituximab-treated patients from the Karolinska University Hospital ( n = 107) were surveyed. LON was defined as an absolute neutrophil count <1500 cells/μl, occurring four weeks to two years following rituximab treatment, or later during sustained B-cell depletion. Serum levels of B-cell-related cytokines and growth factors of the myeloid lineage were determined using enzyme-linked immunosorbent assay...
January 1, 2018: Lupus
https://www.readbyqxmd.com/read/29780032/severe-outcomes-associated-with-respiratory-viruses-in-newborns-and-infants-a-prospective-viral-surveillance-study-in-jordan
#14
Najwa Khuri-Bulos, Lindsey Lawrence, Bhinnata Piya, Li Wang, Christopher Fonnesbeck, Samir Faouri, Asem Shehabi, Sten H Vermund, John V Williams, Natasha B Halasa
OBJECTIVE: To assess virus-specific hospitalisation rates, risk factors for illness severity and seasonal trends in children hospitalised with acute respiratory infections (ARI). DESIGN: Prospective cohort study. SETTING: A government hospital serving low-income and middle-income population in Amman, Jordan. PARTICIPANTS: Children under 2 years of age hospitalised with fever and/or respiratory symptoms (n=3168) from 16 March 2010 to 31 March 2013...
May 20, 2018: BMJ Open
https://www.readbyqxmd.com/read/29774477/cefepime-vs-cefoperazone-sulbactam-in-combination-with-amikacin-as-empirical-antibiotic-therapy-in-febrile-neutropenia
#15
M Ponraj, Biswajit Dubashi, B H Harish, S Kayal, S L Cyriac, Jogamaya Pattnaik, K Ranjith, Unni S Pillai, Naresh Jadhav, Kiran K Matta, Jagdeep Singh, Esha Jaffa, Bhanu Prakash
PURPOSE: Beta lactams are standard empirical therapy for febrile neutropenia (FN). The aim of this study was to evaluate the efficacy and safety of cefepime monotherapy compared with cefoperazone/sulbactam plus amikacin (CS + A) for empirical treatment of high risk FN. METHODS: One hundred seventy-five patients with 336 FN episodes were randomized to receive either cefepime (2 g q8h for adults and 50 mg/kg q8h for children) or CS (2 g q8h for adults and 50 mg/kg q8h for children) plus amikacin (15 mg/kg once a day)...
May 17, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29755847/-18-f-fdg-pet-ct-findings-in-hepatosplenic-gamma-delta-t-cell-lymphoma-case-reports-and-review-of-the-literature
#16
Michael W Cho, Bennett B Chin
Hepatosplenic Gamma Delta T cell lymphoma (γδHSTL) is a rare, highly aggressive, and rapidly lethal T cell lymphoma which manifests 18 F-FDG PET/CT findings that can mimic benign conditions. Patients with γδHSTL present with unexplained symptoms of a hematologic malignancy like the B symptoms of lymphoma including weight loss, fevers, and night sweats, as well as, splenomegaly and hepatomegaly. Thrombocytopenia, anemia, or neutropenia are also common due to spleen, liver and bone marrow involvement. The peripheral blood, however, typically does not show abnormal T cells...
2018: American Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29703015/a-case-report-of-a-very-late-response-to-5-azacytidine-in-a-patient-with-lower-risk-myelodysplastic-syndrome-time-to-update-treatment-guidelines-for-lower-risk-patients
#17
Nikolaos Spetsieris, Panagiotis Diamantopoulos, Konstantinos Zervakis, Nefeli Giannakopoulou, Niki Rougala, Georgios Garefalakis, Vasiliki Skarlatou, Nora-Athina Viniou
RATIONALE: The hypomethylating agent 5-azacytidine has been approved in Europe for patients with intermediate 2 and high (i.e., higher) risk myelodysplastic syndrome according to the International Prognostic Scoring System (IPSS). A total of 91% of all first responses in higher risk patients occur within 6 cycles of treatment; however, data regarding the time to first response in clinical trials with lower risk patients are not available. PATIENT CONCERNS: Our case describes the late response of a lower risk (intermediate 1 according to the IPSS and intermediate according to the IPSS-R) patient to 5-azacytidine treatment...
April 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29693791/feasibility-and-results-of-an-intraarterial-chemotherapy-program-for-the-conservative-treatment-of-retinoblastoma-in-argentina
#18
Santiago Funes, Claudia Sampor, Francisco Villasante, Adriana Fandiño, Julio Manzitti, Mariana Sgroi, Pablo Neira, Laura Peralta, Eduardo Lagomarsino, Paula Schaiquevich, Alejandro Ceciliano, Guillermo L Chantada
BACKGROUND: The feasibility and results of intraarterial chemotherapy, also termed ophthalmic artery chemosurgery (OAC), for retinoblastoma in less developed countries have seldom been reported. PROCEDURE: A retrospective evaluation of a program of OAC in Argentina from 2010 to 2015. RESULTS: Ninety-seven eyes from 81 patients (61 bilateral) were analyzed. In 35 eyes, OAC was given as primary therapy and in 62 it was used for the treatment of tumors with partial response or those relapsing after systemic chemoreduction with focal therapy or external-beam radiotherapy...
April 25, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29690925/staphylococcus-epidermidis-meningitis-in-the-absence-of-a-neurosurgical-device-secondary-to-catheter-related-bloodstream-infection-a-case-report-and-review-of-the-literature
#19
Taro Noguchi, Miki Nagao, Masaki Yamamoto, Yasufumi Matsumura, Toshiyuki Kitano, Akifumi Takaori-Kondo, Satoshi Ichiyama
BACKGROUND: Staphylococcus epidermidis can cause nosocomial meningitis in the presence of prosthetic devices. We describe a case of Staphylococcus epidermidis meningitis in a patient with neutropenia who had no intracranial foreign body, and we review the literature on meningitis that is caused by coagulase-negative Staphylococcus spp. without a neurosurgical device. CASE PRESENTATION: A 47-year-old Japanese man with acute myeloid leukemia receiving chemotherapy through a totally implantable central venous catheter developed fever and headache...
April 25, 2018: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/29687743/clinical-outcomes-of-treatment-with-filgrastim-versus-a-filgrastim-biosimilar-and-febrile-neutropenia-associated-costs-among-patients-with-nonmyeloid-cancer-undergoing-chemotherapy
#20
Lee S Schwartzberg, Lincy S Lal, Sanjeev Balu, Kim Campbell, Lee Brekke, Andrew DeLeon, Caitlin Elliott, Stephanie Korrer
BACKGROUND: Granulocyte colony-stimulating factors such as filgrastim are used to decrease the incidence of febrile neutropenia (FN) among patients with nonmyeloid cancers undergoing chemotherapy treatment. Although the biosimilar filgrastim-sndz has been approved in the United States since 2015, limited real-world comparisons of filgrastim-sndz versus reference filgrastim (filgrastim-ref) have been conducted. OBJECTIVE: To compare FN incidence and assess overall FN-related health care resource utilization and medical costs among U...
April 24, 2018: Journal of Managed Care & Specialty Pharmacy
keyword
keyword
75089
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"